Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2013

View Archived Issues

The discovery and preclinical validation of a potent antitumor peptide vaccine

ONO-6950 shows potential as a novel therapeutic option for bronchial asthma

Researchers from Kineta present novel broad-spectrum antiviral compounds

MedImmune presents results for MEDI-565 and MEDI-575

Medigene and SynCore extend agreement for anticancer candidate

FDA tests potential universal influenza vaccine

Analysis of LRG glycosylation allows for improved diagnostic accuracy in HF

Researchers present preclinical results for leukadherin-1

New TRPV1 ligands patented by Grunenthal

New bispecific antibody fusion proteins disclosed by UCB

Genentech presents new series of BTK inhibitors

Merck & Co. discloses new mGlu2 receptor antagonists

Researchers at Theravance design novel HCV NS5A inhibitors

Cellmid completes acquisition of Advangen

Phase I/IIa study of dendritic cell-based vaccine for AML meets endpoints

Arrowhead Research plans phase I study of ARC-520 for chronic HBV infection

Cellular Dynamics licenses rights to develop cardiomyocyte progenitors for therapeutic use

FDA grants breakthrough therapy designation to Alexion's asfotase alfa

Stribild receives European approval

Nouriast set to launch in Japan

Pharmstandard increases stake in Biolek

FDA issues complete response letter for Valeant's efinaconazole

Omeros plans European phase I study of OMS-721 for atypical hemolytic uremic syndrome

Aslan reports positive data from phase II ALSAN-001 study

First clinical study of Bionor Pharma's HIV vaccine candidate Vacc-C5 completes enrollment

Cenix BioScience to identify predictive biomarkers for Debiopharm's oncology candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...